Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved influenza a antigens

Molecular Therapy

Volumn 22, Issue 3, 2014, Pages 668-674

  Antrobus, Richard D ^a   Coughlan, Lynda ^a   Berthoud, Tamara K ^a   Dicks, Matthew D ^a   Hill, Adrian V S ^a   Lambe, Teresa ^a   Gilbert, Sarah C ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; MATRIX PROTEIN; MATRIX PROTEIN 1; NEUTRALIZING ANTIBODY; NUCLEOPROTEIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADENOVIRUS; ADULT; ARTHRALGIA; ARTICLE; CELLULAR IMMUNITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; EPIDEMIC; ERYTHEMA; FATIGUE; FEBRILE SYMPTOM; FEVER; HEADACHE; HEAT; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNOGENICITY; INFLUENZA A; INFLUENZA VACCINATION; LEUKOPENIA; MALAISE; MYALGIA; NAUSEA AND VOMITING; NORMAL HUMAN; PAIN; PROTEIN EXPRESSION; PRURITUS; SWELLING; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; VIRUS EXPRESSION;

CHIMPANZEE ADENOVIRUS; HUMAN ADENOVIRUS; SIMIAN ADENOVIRUS; VACCINIA VIRUS ANKARA;

ADENOVIRUSES, SIMIAN; ADOLESCENT; ADULT; ANIMALS; ANTIGENS, VIRAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; GENETIC VECTORS; HEK293 CELLS; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; MIDDLE AGED; PAN TROGLODYTES; RECOMBINANT PROTEINS; RNA-BINDING PROTEINS; VACCINATION; VIRAL CORE PROTEINS; VIRAL MATRIX PROTEINS; VIRUS REPLICATION; YOUNG ADULT;

EID: 84895508255     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.284     Document Type: Article

References (39)

1. Molinari, NA, Ortega-Sanchez, IR, Messonnier, ML, Thompson, WW, Wortley, PM, Weintraub, E et al. (2007). The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 25: 5086-5096.
2. Lambert, LC and Fauci, AS (2010). Influenza vaccines for the future. N Engl J Med 363: 2036-2044.
3. Jefferson, T, Di Pietrantonj, C, Al-Ansary, LA, Ferroni, E, Thorning, S and Thomas, RE (2010). Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev: CD004876.
4. Jefferson, T, Rivetti, A, Harnden, A, Di Pietrantonj, C and Demicheli, V (2008). Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev: CD004879.
5. Lambe, T, Carey, JB, Li, Y, Spencer, AJ, van Laarhoven, A, Mullarkey, CE et al. (2013). Immunity against heterosubtypic influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1. Sci Rep 3: 1443.
6. McMichael, AJ, Gotch, FM, Noble, GR and Beare, PA (1983). Cytotoxic T-cell immunity to influenza. N Engl J Med 309: 13-17.
7. Wilkinson, TM, Li, CK, Chui, CS, Huang, AK, Perkins, M, Liebner, JC et al. (2012). Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 18: 274-280.
8. Epstein, SL, Kong, WP, Misplon, JA, Lo, CY, Tumpey, TM, Xu, L et al. (2005). Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 23: 5404-5410.
9. Sridhar, S, Begom, S, Bermingham, A, Hoschler, K, Adamson, W, Carman, W et al. (2013). Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med 19: 1305-1312.
10. Berthoud, TK, Hamill, M, Lillie, PJ, Hwenda, L, Collins, KA, Ewer, KJ et al. (2011). Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis 52: 1-7.
11. Lillie, PJ, Berthoud, TK, Powell, TJ, Lambe, T, Mullarkey, C, Spencer, AJ et al. (2012). Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVANP+ M1, in humans. Clin Infect Dis 55: 19-25.
12. Antrobus, RD, Lillie, PJ, Berthoud, TK, Spencer, AJ, McLaren, JE, Ladell, K et al. (2012). A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVANP+ M1 in adults aged over 50 years. PLoS ONE 7: e48322.
13. O'Hara, GA, Duncan, CJ, Ewer, KJ, Collins, KA, Elias, SC, Halstead, FD et al. (2012). Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis 205: 772-781.
14. Schuldt, NJ, Aldhamen, YA, Godbehere-Roosa, S, Seregin, SS, Kousa, YA and Amalfitano, A (2012). Immunogenicity when utilizing adenovirus serotype 4 and 5 vaccines expressing circumsporozoite protein in naïve and adenovirus (Ad5) immune mice. Malar J 11: 209.
15. Tatsis, N, Fitzgerald, JC, Reyes-Sandoval, A, Harris-McCoy, KC, Hensley, SE, Zhou, D et al. (2007). Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. Blood 110: 1916-1923.
16. Barouch, DH, Kik, SV, Weverling, GJ, Dilan, R, King, SL, Maxfield, LF et al. (2011). International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine 29: 5203-5209.
17. Buchbinder, SP, Mehrotra, DV, Duerr, A, Fitzgerald, DW, Mogg, R, Li, D et al.; Step Study Protocol Team. (2008). Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-ofconcept trial. Lancet 372: 1881-1893.
18. Dicks, MD, Spencer, AJ, Edwards, NJ, Wadell, G, Bojang, K, Gilbert, SC et al. (2012). A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS ONE 7: e40385.
19. Storer, BE (1989). Design and analysis of phase I clinical trials. Biometrics 45: 925-937.
20. Boon, AC, de Mutsert, G, Graus, YM, Fouchier, RA, Sintnicolaas, K, Osterhaus, AD et al. (2002). The magnitude and specificity of influenza A virus-specific cytotoxic T-lymphocyte responses in humans is related to HLA-A and -B phenotype. J Virol 76: 582-590.
21. McElrath, MJ, De Rosa, SC, Moodie, Z, Dubey, S, Kierstead, L, Janes, H et al.; Step Study Protocol Team. (2008). HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372: 1894-1905.
22. Abbink, P, Lemckert, AA, Ewald, BA, Lynch, DM, Denholtz, M, Smits, S et al. (2007). Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 81: 4654-4663.
23. Penaloza-MacMaster, P, Provine, NM, Ra, J, Borducchi, EN, McNally, A, Simmons, NL et al. (2013). Alternative serotype adenovirus vaccine vectors elicit memory T cells with enhanced anamnestic capacity compared to Ad5 vectors. J Virol 87: 1373-1384.
24. Baden, LR, Walsh, SR, Seaman, MS, Tucker, RP, Krause, KH, Patel, A et al. (2013). Firstin- human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001). J Infect Dis 207: 240-247.
25. Chen, H, Xiang, ZQ, Li, Y, Kurupati, RK, Jia, B, Bian, A et al. (2010). Adenovirusbased vaccines: comparison of vectors from three species of adenoviridae. J Virol 84: 10522-10532.
26. Coughlan, L, Bradshaw, AC, Parker, AL, Robinson, H, White, K, Custers, J et al. (2012). Ad5:Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous delivery. Mol Ther 20: 2268-2281.
27. Roberts, DM, Nanda, A, Havenga, MJ, Abbink, P, Lynch, DM, Ewald, BA et al. (2006). Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441: 239-243.
28. Colloca, S, Barnes, E, Folgori, A, Ammendola, V, Capone, S, Cirillo, A et al. (2012). Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med 4: 115ra2.
29. Reyes-Sandoval, A, Sridhar, S, Berthoud, T, Moore, AC, Harty, JT, Gilbert, SC et al. (2008). Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. Eur J Immunol 38: 732-741.
30. Capone, S, Reyes-Sandoval, A, Naddeo, M, Siani, L, Ammendola, V, Rollier, CS et al. (2010). Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates. Vaccine 29: 256-265.
31. Sheehy, SH, Duncan, CJ, Elias, SC, Biswas, S, Collins, KA, O'Hara, GA et al. (2012). Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS ONE 7: e31208.
32. Sheehy, SH, Duncan, CJ, Elias, SC, Collins, KA, Ewer, KJ, Spencer, AJ et al. (2011). Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol Ther 19: 2269-2276.
33. Sheehy, SH, Duncan, CJ, Elias, SC, Choudhary, P, Biswas, S, Halstead, FD et al. (2012). ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol Ther 20: 2355-2368.
34. Ogwang, C, Afolabi, M, Kimani, D, Jagne, YJ, Sheehy, SH, Bliss, CM et al. (2013). Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults. PLoS ONE 8: e57726.
35. Barnes, E, Folgori, A, Capone, S, Swadling, L, Aston, S, Kurioka, A et al. (2012). Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 4: 115ra1.
36. McConkey, SJ, Reece, WH, Moorthy, VS, Webster, D, Dunachie, S, Butcher, G et al. (2003). Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 9: 729-735.
37. Warming, S, Costantino, N, Court, DL, Jenkins, NA and Copeland, NG (2005). Simple and highly efficient BAC recombineering using galK selection. Nucleic Acids Res 33: e36.
38. Berthoud, TK, Fletcher, H, Porter, D, Thompson, F, Hill, AV and Todryk, SM (2009). Comparing human T cell and NK cell responses in viral-based malaria vaccine trials. Vaccine 28: 21-27.
39. Antrobus, RD, Berthoud, TK, Mullarkey, CE, Hoschler, K, Coughlan, L, Zambon, M et al. (2014). Coadministration of seasonal influenza vaccine and MVA-NP+m1 simultaneously achieves potent humoral and cell-mediated responses. Mol Ther 22: 233-238.